The Effect of High-Dose Thiotepa, Alone Or in Combination with Other
Bone Marrow Transplantation (2007) 40, 891–896 & 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00 www.nature.com/bmt ORIGINAL ARTICLE The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation A Abdul-Hai, L Weiss, D Ergas, IB Resnick, S Slavin and MY Shapira Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah–Hebrew University Medical Center, Jerusalem, Israel The use of thiotepa (TH) is increasing, especially in stem Introduction cell transplantation, mainly due to its safety and blood– brain barrier penetration. We evaluated the use of TH in a Thiotepa (TH, triethylene thiophosphoramide), an ethylene murine model simulating autologous stem cell transplan- amide, developed by Lederle Laboratories in 1952, tation, with or without additional agents. Between 1 and possesses mechlorethamine-like alkylating activity and 11 days following inoculation of BALB/c mice with 105– has been used clinically for over 35 years.1 It is of particular 108 B-cell leukemia (BCL1) cells (simulating pre-trans- use in breast cancer, mainly as second-line treatment.2 plant leukemia loads), each group received an ‘induction- TH has been given intrathecally for carcinomatous like’ irradiation and/or cytotoxic regimen. Animals were meningitis, and intravesically for bladder carcinoma.3,4 either followed without treatment, or an adoptive transfer Mild-to-moderate activity was observed in several solid (AT) was performed to untreated BALB/c mice. Admi- tumors and hematological malignancies.1,5 There has nistered alone without AT, high-dose TH did not change been, however, a sustained interest in defining clinical roles the time to appearance of leukemia.
[Show full text]